Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
New Science Ventures
AddedFeb 13, 2024
UpdatedJun 28, 2026
New Science Ventures

New Science Ventures

Operating

New Science Ventures, LLC: A US-based venture capital firm investing in life science and IT sectors.

Location
New York City, NY, US
Founded
2004
Firm
Compare
Portfolio
Employees
Website

Investments

Glydways
Glydways

Total Raised

$91.2M

Rounds

3

Series B$56MOctober 2023
VUV Analytics
VUV Analytics

Total Raised

$39.8M

Rounds

6

Series Unknown$20MFebruary 2023
Series B$6.5MAugust 2016
Brightvolt
Brightvolt
Public

Total Raised

$116.8M

Rounds

16

Series B$16MOctober 2021
Convertible Note$6MJanuary 2019
Series B$12MSeptember 2016
Series A$4MNovember 2013
Analog Inference
Analog Inference

Total Raised

$50.5M

Rounds

4

Series AJune 2021
Phase Four
Phase Four
Acquired

Total Raised

$29.6M

Rounds

7

Series B$26MJune 2021
ABL Space Systems
ABL Space Systems

Total Raised

$419M

Rounds

4

Series A$49MMarch 2020
Dust Identity
Dust Identity

Total Raised

$52.3M

Rounds

3

Series A$10MJuly 2019
Seed$2.3MNovember 2018
PlanetiQ
PlanetiQ

Total Raised

$37.6M

Rounds

3

Series B$18.7MJuly 2019
Svelte Medical Systems
Svelte Medical Systems

Total Raised

$128.4M

Rounds

11

Series Unknown$22MOctober 2018
Private Equity$44.4MFebruary 2016
Series Unknown$5MMarch 2014
Kateeva
Kateeva

Total Raised

$126M

Rounds

2

Series E$88MMay 2016
Series D$38MSeptember 2014
Fuzzy Logix
Fuzzy Logix

Total Raised

$5.5M

Rounds

1

Series A$5.5MNovember 2015
Vorago Technologies
Vorago Technologies

Total Raised

$22.5M

Rounds

5

Series D$10MSeptember 2015
Ralexar Therapeutics
Ralexar Therapeutics

Total Raised

$41.6M

Rounds

3

Series A$26.9MApril 2015
PerceptiMed
PerceptiMed

Total Raised

$11M

Rounds

4

Series A$5.4MMarch 2015
TigerConnect
TigerConnect

Total Raised

$448.9M

Rounds

8

Series B$23MJanuary 2014
Nexeption
Nexeption

Total Raised

$21.5M

Rounds

1

Series A$21.5MJanuary 2014
Resolve Therapeutics
Resolve Therapeutics

Total Raised

$8.9M

Rounds

3

Series B$5.8MNovember 2012